TY - JOUR AU - Sharma, Shashikant AU - Gupta, Vishali AU - Maiti, Aniruddha AU - Natesh, Sribhargava AU - Saxena, Sandeep AU - Dave, Vivek AU - Parmar, Vimal AU - Sampangi, Raju AU - Murthy, Hemanth AU - Dharwadkar, Sandhya AU - Yadav, Naresh Kumar AU - Joshi, Shrinivas AU - Mayor, Rahul AU - Ratra, Dhanashree AU - Basu, Soumyava AU - Goel, Neha AU - Chaturvedi, Alok AU - Patel, Ronak AU - Jose, Vinu PY - 2021 DA - 2021/03/24 TI - Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study JO - International Journal of Retina and Vitreous SP - 24 VL - 7 IS - 1 AB - Razumab™ (world’s first biosimilar ranibizumab) is approved for several macular disorders including wet age-related macular degeneration (AMD). We evaluated the safety and efficacy of biosimilar ranibizumab in wet AMD. SN - 2056-9920 UR - https://doi.org/10.1186/s40942-021-00293-w DO - 10.1186/s40942-021-00293-w ID - Sharma2021 ER -